Life Extension Magazine®

Issue: Jul 2011

An Epidemic of Denial

Nearly two-thirds of Americans are now medically classifiable as overweight or obese. Yet 30% of overweight individuals believe they’re at a healthy weight, and 70% of obese individuals feel they’re simply overweight. Scientists have discovered a novel blend of plant extracts that can safely induce significant fat loss in humans.

By William Faloon.

William Faloon
William Faloon
An Epidemic of Denial

About 65% of Americans are now overweight or obese, and this excess weight costs our nation an estimated $93 billion in annual medical bills.1

According to a recent survey, about 30% of overweight individuals think they are normal size, and 70% of Americans classified as obese felt they were simply overweight.2 Since it has become “normal” to carry excess body fat, we understand why so many are in a state of denial regarding their corpulence.

The problem is that excess body fat is more than a cosmetic issue. The words overweight and obese are medical terms. They mean a person’s surplus body fat increases risks of illnesses like cancer,3-9 diabetes,10-12 heart disease,13-18 and stroke.19-23

A study by the Organization for Economic Cooperation and Development predicts that by the year 2020 nearly 75% of the American population will be overweight or obese.24 This exploding epidemic has led to the shocking prediction that in less than nine years, half of all Americans will be either pre-diabetic or suffer full-blown type 2 diabetes.25

Our early warning of an out-of-control health care crisis caused by so many overweight Americans is turning into a stark reality.

The challenge facing most people is how to remove surplus body fat stores.

There is encouraging news. In a series of meticulously conducted studies, researchers have demonstrated that a novel blend of plant extracts can simultaneously attack the fundamentals of obesity and induce significant fat loss in humans.

Scientists long ago discovered that people gain weight because their bodies accumulate too many bloated fat cells (adipocytes).26,27 Up until now, however, little could be done to reverse this deadly trend of adipocyte expansion.

Medical Establishment Remains Light Years Behind

When doctors are asked what can be done to avert the impending diabetes/obesity epidemic, the pathetic answers (such as eat less and exercise) reveal that mainstream medicine has little idea how to solve this problem.

At a medical conference I spoke at regarding this issue, I told the physicians that doctors are committing malpractice if they fail to take aggressive actions to reduce every overweight patient’s fat mass. It would be like observing a large melanoma lesion on a patient’s skin and letting the patient walk out of the office without doing something about it.

Medical Establishment Remains Light Years Behind

Most medical disorders can be traced to surplus fat mass. This can range from an infection (related to obesity-induced immune suppression) to crippling arthritis.28-35 Obesity has been shown to impede the activity of natural killer cells, a type of white blood cell that reduces viral spread by killing infected cells.29,36-38 In fact, obesity has been shown to increase the risk for complications of the dreaded H1N1 influenza infection.39,40

I tell doctors that common symptoms their patients present with are often caused by excess body weight and that it is impossible to optimally treat these patients without helping them to shed fat pounds. My objective is to enlighten physicians about the power of their prescription pads to introduce medications (such as acarbose41,42 and metformin43-46) that can safely help facilitate weight loss.

To fully inform physicians about the weapons at their disposal, I often give them a copy of our Life Extension® Weight Loss Guide that discusses the use of certain prescription medications, hormones, nutrients, and lifestyle changes that have clinically demonstrated benefits.

It is imperative that physicians don’t fall into the same lethal state of denial that overweight individuals have. Doctors are seeing so many obese patients in their office that they too often overlook the obvious necessity to implement aggressive fat loss interventions.

What Causes Fat to Accumulate on our Bodies?

Few people understand what is happening in their bodies as they accumulate fat pounds. To state it in the simplest terms, we become overweight because:

1. Fat cells (adipocytes) become bloated in our bodies from storage of surplus calories from food as body fat,

and

2. Fat cells become dysfunctional, resulting in metabolic derangements including impairments in burning of fatty acids for energy.48

What Causes Fat to Accumulate on our Bodies?

There are many reasons why we accumulate dysfunctional, bloated adipocytes as we age, especially in the abdominal area. The ultimate target of any obesity reversal program is to target bloated, dysfunctional fat cells.

Interventions focused upon bloated, dysfunctional adipocytes have been attempted by indirect methods, such as speeding up metabolic rate to burn excess fat mass stored in the body. Scientists have found limited success when employing certain adipocyte-reducing approaches—yet the obesity epidemic worsens each year nonetheless.

The problem has been that up until now, little has been available to directly target critical mechanisms responsible for bloated, dysfunctional adipocytes.

Herculean Effort Leads to Discovery of Anti-Adipocyte Plant Extracts

A group of scientists screened over one thousand plant extracts with the objective of identifying ones able to:

  1. Reduce the differentiation of pre-adipocytes into bloated, dysfunctional adipocytes (fat storage cells).
  2. Reduce excessive fatty acid uptake of existing adipocytes.
  3. Enhance lipolysis­—the breakdown of stored fat in adipocytes.

Extensive testing uncovered two plant extracts that function via multiple mechanisms to reverse the metabolic dysfunction associated with bloated fat cells.49

In one of the laboratory tests, fat accumulation in cells was inhibited by a remarkable 48.5% when treated with one of these plant extracts compared to control cells. The other component of this dual plant extract was shown to reduce fat accumulation in cells by a stunning 65.9% compared with control. 49

When measuring the breakdown of stored fat (lipolysis), 55.8% more fat was broken down in adipocytes using one of the components of this dual plant extract compared to control.49

These in vitro studies showed the potent efficacy of these plant extracts to reduce fat accumulation in cells and promote fat burning (breakdown) in adipocytes. The next step was to study the effects of this novel blend of plant extracts in the whole animal (in vivo) model.49

Using these Plant Extracts to Prevent Obesity in Rats

A group of healthy young adult rats were fed a high-fat diet for eight weeks. As expected, those that did not take the plant extracts (the control group) rapidly gained weight.

The rats taking the plant extracts showed a reduced body weight gain of 700% compared to the controls at the end of eight weeks.49 These were the same plant extracts that blocked fat accumulation by 48.5% and 65.9% in the cellular model.

This study showed that these plant extracts decreased diet-induced obesity in young adult rats.49

The final and obvious question is what effect these plant extracts will have on aging humans who are already overweight or obese…which represents the majority of the adult American population today!

A Key Human Clinical Study

Humans accumulate surplus fat because of multiple changes that occur as a result of normal aging—in addition to poor lifestyle choices. When simplistic methods to reduce body fat are utilized, the results often prove disappointing.

As you will learn in this month’s issue, scientists have identified many of the factors that conspire to cause unwanted weight gain and preclude it from being removed.

What has us most excited are the brand new findings showing that a novel blend of two plant extracts functions via six different mechanisms to:

  • Target progenitor fat cells (pre-adipocytes) to keep them from producing dysfunctional fat cells;
  • Reduce fat accumulation (adipogenesis) in adipocytes;
  • Break down excess fat (lipolysis) in existing adipocytes.

These cellular anti-fat functions are critical for weight loss success, though most dieters don’t yet understand this.

In this key human clinical study using these plant species, 60 obese adults were recruited and divided into two groups. One arm of 30 patients functioned as the placebo while a second group of 30 patients received the two plant extracts. Both groups followed a 2,000 calorie-a-day diet and were asked to walk 30 minutes five days a week.50

After eight weeks the group receiving this novel blend of two plant extracts experienced statistically significant improvements in many parameters including:50

  • Reduction of 4.05 inches in the abdomen—which was 2 times greater than the placebo arm.
  • Reduction in body mass index (BMI) of 2.05—which was 3.9 times greater than placebo.
  • Reduction in total body weight of 11.4 pounds—which was 3.7 times greater than the placebo arm.

What impressed the researchers who conducted this randomized, double-blind, placebo-controlled study was that noticeable reduction in waist and hip circumference, as well as body weight, occurred within the first 14 days!

The dual plant extract group also showed significant reduction in the waist-to-hip ratio, 2.2 times greater than the placebo group. This is important because improvements in the waist-hip ratio indicate the more dangerous visceral belly fat is being lost.

Also impressive was the trend toward improvement in the hormone adiponectin in the group taking the plant extracts.50 A higher level of adiponectin is encouraging because this hormone is known to improve insulin sensitivity51-55 and potentially protect cardiovascular health.56-59

Trends toward reduced levels of glucose and cholesterol in the dual plant extract arm reflect improved status of fat metabolism and reduced body fat stores.50

New Study Confirms Overweight People Die Sooner

The lethal impact of carrying surplus fat pounds may seem obvious. Until recently, however, no one could point to a study that did not have confounding flaws such as including those with pre-existing heart disease, cancer, etc.

A pooled analysis involving 1.46 million men and women was published in the New England Journal of Medicine that measured risk of dying with body mass index (BMI).47 Those with pre-existing illness and smokers were excluded.

The findings showed that compared with women of normal weight during the study period:

  • Overweight women (BMI between 25.0 and 29.9) were 13% more likely to die;
  • Moderately obese women (BMI between 30.0 and 34.9) were 44% more likely to die;
  • Severely obese women (BMI between 35.0 and 39.9) were 88% more likely to die;
  • Morbidly obese women (BMI between 40.0 and 49.9) were 151% more likely to die.

The body weight/risk of dying pattern was similar for men. The lowest mortality risks were for the people who had a body mass index (BMI) of 20 to 24.9.

The “body mass index” or BMI is based on how much someone weighs in relationship to their height. The BMI is not a completely accurate mortality predictor as a large waist circumference even in those in the normal BMI range can increase one’s risk of early death.

A Second, Key Human Study

The findings from the trial described above indicate significant weight loss as well as improvement in several metabolic parameters with a natural plant-based product. Contrast this fact with many FDA-approved weight loss drugs subsequently withdrawn because of lethal side effects.

The plant species used in these studies have been consumed by humans for thousands of years, and no known adverse effects have been shown. Unlike natural plant extracts, weight loss drugs comprise synthetic chemicals with little or no history of human use.

Using these Plant Extracts to Prevent Obesity in Rats

The findings from the first study described are supported by a second, similarly designed trial.

In the second human study, 60 obese subjects were evaluated at baseline. They were then divided into three groups that consisted of a placebo arm, an active arm receiving one plant extract, and another active arm that received a dual plant extract.49

All participants followed a 2,000 calorie-per-day diet and were asked to walk for 30 minutes five times a week for 8 weeks.

After eight weeks the group receiving the dual plant extract experienced statistically significant changes in their abdominal circumference, total body weight, and their hip circumference similar to those seen in the first study mentioned above.49

These confirmatory findings indicate that this novel dual plant extract may enable aging humans to safely shed unwanted body fat stores.

Obesity arises from the increased size of individual adipocytes (fat cells) due to enhanced lipid (fat) accumulation. It worsens as adipocytes transform into dysfunctional, bloated adipocytes.

This novel blend of plant extracts has been shown in cell cultures to reduce the ability of progenitor fat cells (pre-adipocytes) to transform into bloated fat cells.49 Cell data also shows that components of this dual plant extract reduce the amount of fatty acids taken up by adipocytes and facilitates the breakdown of fat stored in existing adipocytes.50

When tested in obese human study subjects, this dual plant extract induced noticeable effects at 14 days and significant benefits at eight weeks compared with placebo.

There has never been a formulation available that directly functions via these specific anti-adipocyte mechanisms. The first article in this month’s issue describes in molecular detail how this new dual plant extract can help aging people remove excess body fat stores.

Chronically Bloated Bloodstreams an Obesity Culprit

Chronically Bloated Bloodstreams an Obesity Culprit

Another culprit involved in age-related weight gain is that our bloodstreams become chronically bloated with glucose, insulin, and triglycerides.60-64 One reason for this is that aging people lose their sensitivity to insulin.

As glucose accumulates in the bloodstream, the pancreas secretes insulin to reduce blood glucose. (Type 2 diabetes results when the pancreas can no longer produce enough insulin to control blood sugar levels as cells throughout the body lose sensitivity to insulin.) In the presence of high fasting insulin (hyperinsulinemia), sustained weight loss can become difficult to achieve.

A diet high in unhealthy fats and simple carbohydrates results in chronically elevated blood triglyceride levels. These triglycerides further impair insulin sensitivity and contribute to glucose dysregulation and elevated insulin levels.65

Life Extension’s longstanding position is that diabetes and obesity prevention begins by eating less calories. Futhermore, blocking the negative impact of excess amounts of simple carbohydrate and fat calories by taking certain nutrients and/or drugs before heavy meals can also reduce the calorie burden.

Further steps to improve systemic insulin sensitivity can result in a reversal of metabolic derangements associated with obesity, including the insulin resistance observed in the majority of patients with type 2 diabetes mellitus.

Study subjects taking the new dual plant extract showed reductions in triglyceride and glucose blood levels.50 This indicates these plants are functioning across a broad spectrum of biological activities to correct underlying metabolic imbalances that predispose aging humans to weight gain.

Physicians Urged to Recognize Today’s Obesity Epidemic

As I was writing this editorial, a commentary appeared in the Journal of the American Medical Association (JAMA) discussing the difficulties of examining obese patients because of the thick layer of adipose (fat) tissue that envelopes their vital tissues. It suggested that physicians better educate themselves in order to ensure good care of obese patients.67

The JAMA article opened up by stating, “The notion of the standard 70 kilogram (154 pound) patient is outdated.”

The sad fact is that this deadly epidemic is spreading across all ages including one-third of 9-month-olds who are already obese or overweight.68

A Powerful New Weapon…

According to the US Depart-ment of Agriculture, Americans consumed an extra 331 calories each day in the year 2006, compared with 1978. That translates into roughly 34 pounds of stored body fat.66

Virtually everyone consumes excess calories that they could cut out without depriving themselves. It is not unreasonable for a doctor to ask an overweight patient to determine which calories are the least important and to delete these from one’s normal diet. Examples are eliminating bread and butter before a meal or a dessert after a meal if these are not vital to achieving satiety. Once one gets used to cutting calories that are not that important, it is easy to stay away from them over the long term. An article in this month’s issue by the founders of the CR Way Program sheds new light on the multiple benefits that occur when humans reduce their calorie burdens.

A problem most in the Western world face is that they consume too many calories even when trying to cut back. This is why it is so important for anyone seeking to lose weight (and live longer) to reduce the number of ingested calories that make it into the bloodstream. Fortunately, there are nutrients and safe medications that neutralize enzymes in the digestive tract that break down food for rapid absorption into the bloodstream. We urge any overweight member to take nutrients and/or medications before meals that impede calorie absorption to lower blood glucose, insulin, and triglycerides.

A Powerful New Weapon…

You might think that cutting back a bit on how much you eat and impeding absorption of fats and carbohydrates would induce considerable weight loss. For some individuals, significant weight loss will occur. For most overweight and obese individuals, however, they need to improve calorie utilization at the cellular level and mobilize their surplus fat stores in order to achieve a safe body weight.

Fortunately, a novel dual plant extract technology has been developed that functions to inhibit the development of bloated, dysfunctional adipocytes, impede the uptake of fatty acids into adipocytes, and facilitate the breakdown of stored lipids in existing adipocytes.

The dual plant extract described in the first article in this month’s issue provides a powerful new weapon for those seeking to achieve healthier body weight, especially when it comes to reducing stubborn visceral fat that accumulates in the bellies of so many aging individuals.

For longer life,

For Longer Life

William Faloon

References

1. Available at: http://www.usatoday.com/news/health/2003-05-13-obesity-usat_x.htm. Accessed April 21, 2011.

2. Available at: http://www.harrisinteractive.com/NewsRoom/HarrisPolls/tabid/447/mid/1508/articleId/558/ctl/ReadCustom%20Default/Default.aspx.
Accessed April 11, 2011.

3. Reeves GK, Pirie K, Beral V, et al. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ. 2007 Dec 1;335(7630):1134.

4. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004 Aug;4(8):579-91.

5. Schapira DV, Kumar NB, Lyman GH. Estimate of breast cancer risk reduction with weight loss. Cancer. 1991 May 15;67(10):2622-5.

6. Lorincz AM, Sukumar S. Molecular links between obesity and breast cancer. Endocr Relat Cancer. 2006;13:279–92.

7. Pan SY, DesMeules M, Morrison H, Wen SW. Obesity, high energy intake, lack of physical activity, and the risk of kidney cancer. Cancer Epidemiol Biomarkers Prev. 2006 Dec;15(12):2453-60.

8. Ahrens W, Timmer A, Vyberg M, et al. Risk factors for extrahepatic biliary tract carcinoma in men: medical conditions and lifestyle: results from a European multicentre case-control study. Eur J Gastroenterol Hepatol. 2007 Aug;19(8):623-30.

9. Ceschi M, Gutzwiller F, Moch H, Eichholzer M, Probst-Hensch NM. Epidemiology and pathophysiology of obesity as cause of cancer. Swiss Med Wkly. 2007;137:50–6.

10. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006 Dec 14;444(7121):881-7.

11. Hirani V, Zaninotto P, Primatesta P. Generalised and abdominal obesity and risk of diabetes, hypertension and hypertension-diabetes co-morbidity in England. Public Health Nutr. 2008 May;11(5):521-7.

12. Meisinger C, Doring A, Thorand B, Heier M, Lowel H. Body fat distribution and risk of type 2 diabetes in the general population: are there differences between men and women? The MONICA/KORA Augsburg cohort study. Am J Clin Nutr. 2006 Sep;84(3):483-9.

13. Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med. 2002 Aug 1;347(5):305-13.

14. Logue J, Murray HM, Welsh P, et al. Obesity is associated with fatal coronary heart disease independently of traditional risk factors and deprivation. Heart. 2011 Apr;97(7):564-8.

15. Arnlov J, Ingelsson E, Sundstrom J, Lind L. Impact of body mass index and the metabolic syndrome on the risk of cardiovascular disease and death in middle-aged men. Circulation. 2010 Jan 19;121(2):230-6.

16. Wong CY, O’Moore-Sullivan T, Leano R, Byrne N, Beller E, Marwick TH. Alterations of left ventricular myocardial characteristics associated with obesity. Circulation. 2004 Nov 9;110(19):3081-7.

17. Safar ME, Czernichow S, Blacher J. Obesity, arterial stiffness, and cardiovascular risk. J Am Soc Nephrol. 2006 Apr;17(4 Suppl 2):S109-11.

18. Calabro P, Yeh ET. Intra-abdominal adiposity, inflammation, and cardiovascular risk: new insight into global cardiometabolic risk. Curr Hypertens Rep. 2008 Feb;10(1):32-8.

19. Suk SH, Sacco RL, Boden-Albala B, et al. Abdominal obesity and risk of ischemic stroke: the Northern Manhattan Stroke Study. Stroke. 2003 Jul;34(7):1586-92.

20. Yatsuya H, Folsom AR, Yamagishi K, North KE, Brancati FL, Stevens J. Race- and sex-specific associations of obesity measures with ischemic stroke incidence in the Atherosclerosis Risk in Communities (ARIC) study. Stroke. 2010 Mar;41(3):417-25.

21. O’Donnell MJ, Xavier D, Liu L, et al. Risk factors for ischaemic and intracerebral aemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet. 2010 Jul 10;376(9735):112-23.

22. Kurth T, Gaziano JM, Berger K, et al. Body mass index and the risk of stroke in men. Arch Intern Med. 2002 Dec 9-23;162(22):2557-62.

23. Bosnar-Pureti M, Basi-Kes V, Jurasi MJ, Zavoreo I, Demarin V. The association of obesity and cerebrovascular disease in young adults--a pilot study. Acta Clin Croat. 2009 Sep;48(3):295-8.

24. Available at: http://www.wfaa.com/news/health/Study-75-percent-of-Americans-will-be-overweight-by-2020-103639534.html. Accessed April 21, 2011.

25. Available at: http://www.unitedhealthgroup.com/hrm/UNH_WorkingPaper5_FactSheet.pdf. Accessed April 12, 2011.

26. Krotkiewski M, Bjorntorp P, Sjostrom L, Smith U. Impact of obesity on metabolism in men and women. Importance of regional adipose tissue distribution. J Clin Invest. 1983 Sep;72(3):1150-62.

27. Arner E, Westermark PO, Spalding KL, et al. Adipocyte turnover: relevance to human adipose tissue morphology. Diabetes. 2010 Jan;59(1):105-9.

28. Karlsson EA, Beck MA. The burden of obesity on infectious disease. Exp Biol Med (Maywood). 2010 Dec;235(12): 1412-24.

29. Smith AG, Sheridan PA, Harp JB, Beck MA. Diet-induced obese mice have increased mortality and altered immune responses when infected with influenza virus. J Nutr. 2007 May;137(5):1236-43.

30. Louie JK, Acosta M, Samuel MC, et al. A novel risk factor for a novel virus: obesity and 2009 pandemic influenza A (H1N1). Clin Infect Dis. 2011 Feb;52(3):301-12.

31. Karlsson EA, Sheridan PA, Beck MA. Diet-induced obesity impairs the T cell memory response to influenza virus infection. J Immunol. 2010 Mar 15;184(6):3127-33.

32. Leveille SG, Wee CC, Iezzoni LI. Trends in obesity and arthritis among baby boomers and their predecessors, 1971-2002. Am J Public Health. 2005 Sep;95(9):1607-13.

33. Voigt LF, Koepsell TD, Nelson JL, Dugowson CE, Daling JR. Smoking, obesity, alcohol consumption, and the risk of rheumatoid arthritis. Epidemiology. 1994 Sep;5(5):525-32.

34. Badley EM, Ansari H. Arthritis and arthritis-attributable activity limitations in the United States and Canada: a cross-border comparison. Arthritis Care Res (Hoboken). 2010 Mar;62(3):308-15.

35. Available at: http://www.cdc.gov/mmwr/pdf/wk/mm5939.pdf. Accessed April 12, 2011.

36. O’Shea D, Cawood TJ, O’Farrelly C, Lynch L. Natural killer cells in obesity: impaired function and increased susceptibility to the effects of cigarette smoke. PLoS One. 2010 Jan 25;5(1):e8660.

37. Available at: http://www.nature.com/oby/journal/v17/n3/full/oby2008565a.html. Accessed April 13, 2011.

38. Available at: http://endo.endojournals.org/cgi/reprint/149/7/3370.pdf. Accessed April 13, 2011.

39. Nave H, Beutel G, Kielstein JT. Obesity-related immunodeficiency in patients with pandemic influenza H1N1. Lancet Infect Dis. 2011 Jan;11(1):14-5.

40. Centers for Disease Control and Prevention (CDC). Hospitalized patients with novel influenza A (H1N1) virus infection - California, April-May, 2009. MMWR Morb Mortal Wkly Rep. 2009 May 22;58(19):536-41.

41. Pan CY, Gao Y, Chen JW, et al. Efficacy of acarbose in Chinese subjects with impaired glucose tolerance. Diabetes Res Clin Pract. 2003 Sep;61(3):183-90.

42. Hauner H. The impact of pharmacotherapy on weight management in type 2 diabetes. Int J Obes Relat Metab Disord. 1999 Jun;23 Suppl 7:S12-7.

43. Golay A. Metformin and body weight. Int J Obes (Lond). 2008 Jan;32(1):61-72.

44. Desilets AR, Dhakal-Karki S, Dunican KC. Role of metformin for weight management in patients without type 2 diabetes. Ann Pharmacother. 2008 Jun;42(6):817-26.

45. Paolisso G, Amato L, Eccellente R, et al. Effect of metformin on food intake in obese subjects. Eur J Clin Invest. 1998 Jun;28(6):441-6.

46. Fontbonne A, Charles MA, Juhan-Vague I, et al. The effect of metformin on the metabolic abnormalities associated with upper body fat distribution. Results of the BIGPRO 1 trial. Diabetes Care. 1996 Sept; 19:920-6.

47. Berrington de Gonzalez A, Hartge P, Cerhan JR, et al. Body-mass index and mortality among 1.46 million white adults. N Engl J Med. 2010 Dec 2;363(23):2211-9.

48. Guo W, Pirtskhalava T, Tchkonia T, et al. Aging results in paradoxical susceptibility of fat cell progenitors to lipotoxicity. Am J Physiol Endocrinol Metab. 2007 Apr;292(4):E1041-51.

49. Results based on initial analysis of unpublished research data.

50. Lau FC, Golakoti T, Krishnaraju AV, Sengupta K, Bagchi D. Efficacy and tolerability of Merastin™- A randomized, double-blind, placebo-controlled study. FASEB J. April 2011; 25:(Meeting Abstract Supplement) 601.9. Presented at Experimental Biology 2011, Washington, DC. April 10, 2011. Program No. 601.9, Poster No. A278.

51. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001;7:941-6.

52. Shand BI, Scott RS, Elder PA, George PM. Plasma adiponectin in overweight, nondiabetic individuals with or without insulin resistance. Diabetes Obes Metab. 2003 Sep;5(5):349-53.

53. Yamamoto Y, Hirose H, Saito I, Nishikai K, Saruta T. Adeponectin, an adipocyte-derived protein, predicts future insulin resistance: two-year follow-up study in Japanese population. J Clin Endocrinol Metab. 2004 Jan;89(1):87-90.

54. Ryo M, Nakamura T, Kihara S, et al. Adeponectin as a biomarker of the metabolic syndrome. Circ J. 2004 Nov;68(11):975-81.

55. Fasshauer M, Paschke R, Stumvoll M. Adeponectin, obesity, and cardiovascular disease. Biochimie. 2004 Nov;86(11):779-84.

56. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA. 2004 Jul 7;292(1):40.

57. Han SH, Quon MJ, Kim JA, Koh KK. Adeponectin and cardiovascular disease: response to therapeutic interventions. J Am Coll Cardiol. 2007 Feb 6;49(5):531-8.

58. Kumada M, Kihara S, Sumitsuji S, et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol. 2003 Jan 1;23(1):85-9.

59. Okui H, Hamasaki S, Ishida S, et al. Adeponectin is a better predictor of endothelial function of the coronary artery than HOMA-R, body mass index, immunoreactive insulin, or triglycerides. Int J Cardiol. 2008 May 7;126(1):53-61.

60. Ribeiro RT, Afonso RA, Guarino MP, Macedo MP. Loss of postprandial insulin sensitization during aging. J Gerontol A Biol Sci Med Sci. 2008 Jun;63(6):560-5.

61. Preuss HG. Effects of glucose/insulin perturbations on aging and chronic disorders of aging: the evidence. J Am Coll Nutr. 1997 Oct;16(5):397-403.

62. Godsland IF, Crook D, Walton C, Wynn V, Oliver MF. Influence of insulin resistance, secretion, and clearance on serum cholesterol, triglycerides, lipoprotein cholesterol, and blood pressure in healthy men. Arterioscler Thromb. 1992 Sep;12(9):1030-5.

63. Ginsberg HN, Zhang YL, Hernandez-Ono A. Regulation of plasma triglycerides in insulin resistance and diabetes. Arch Med Res. 2005 May-Jun;36(3):232-40.

64. Simental-Mendía LE, Rodriguez-Moran M, Guerrero-Romero F. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab Syndr Relat Disord. 2008 Dec;6(4):299-304.

65. Chalkley SM, Hettiarachchi M, Chisholm DJ, Kraegen EW. Long-term high-fat feeding leads to severe insulin resistance but not diabetes in Wistar rats. Am J Physiol Endocrinol Metab. 2002 Jun;282(6):E1231-8.

66. Available at: http://blogs.wsj.com/health/2010/05/12/white-house-obesity-report-suggests-more-pe-is-not-enough/. Accessed April 13, 2011.

67. Silk AW, McTigue KM. Reexamining the physical examination for obese patients.
JAMA. 2011 Jan 12;305(2):193-4.

68. Moss BG, Yeaton WH. Young children’s weight trajectories and associated risk factors: results from the Early Childhood Longitudinal Study-Birth Cohort. Am J Health Promot. 2011 Jan-Feb;25(3):190-8.

Subscribe to Life Extension Magazine®

Subscribe Now

Advertise in Life Extension Magazine®

Learn More